TA90-IC, a new marker for advanced colon cancer

Annals of Surgical Oncology

Volumn 7, Issue 5, 2000, Pages 352-356

  Habal, Nizar ^a   Gupta, Rishab K ^a   Bilchik, Anton J ^a   Johnson, Timothy ^a   Morton, Donald L ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Carcinoembryonic antigen; Colon cancer; TA90 circulating immune complexes

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; GLYCOPROTEIN; TUMOR MARKER;

ADULT; AGED; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER GROWTH; CANCER SCREENING; CANCER STAGING; COLON CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OPTICAL DENSITY;

EID: 0034047873     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10434-000-0352-y     Document Type: Article

References (16)

1. Ransohoff DF, Lang CA. Screening for colorectal cancer with fecal occult blood test: a background paper. Ann Intern Med 1997;126:811-22.
2. Atkin WS, Hart A, Edwards R, et al. Uptake, yield of neoplasia, and adverse effects of flexible sigmoidoscopy screening. Gut 1998; 42:560-5.
3. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991;5:344-66.
4. Moertel CG, Fleming TR, McDonald JS, Haller DG, Laurie JA, Tangen C. An evaluation of CEA test for monitoring patients with resected colon cancer. JAMA 1993;270:943-7.
5. Carpelan-Holmstrom MA, Haglund CH, Roberts PJ. Differences in serum tumor markers between colon and rectal cancer. Dis Colon Rectum 1996;39:799-805.
6. Von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of four tumor markers, CA242, CA19/9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996;16:2325-2332.
7. Carpelan-Holmstrom MA, Haglund C, Jarvinen HJ, Roberts PJ. Serum CA242. and CEA detect different patients with recurrent colorectal cancer. Anticancer Res 1996;16:981-6.
8. Nilsson O, Johansson C, Glimelius B, et al. Sensitivity and specificity of CA242 in gastro-intestinal cancer: a comparison with CEA, CA50 and CA19/9. Br J Cancer 1992;65:215-21.
9. Euhus DM, Gupta RK, Morton DL. Characterization of 90-100 kDa tumor-associated antigen in the sera of melanoma patients. Int J Cancer 1990;45:1065-70.
10. Gupta RK, Morton DL. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated antigen-specific immune complexes in cancer patients. J Clin Lab Anal 1992;6:329-36.
11. Wong JH, Xu SH, Gupta RK, Morton DL. Tumor-associated antigen immune complexes, a potential marker for recurrent melanoma. Arch Surg 1990;125:187-91.
12. Hsueh EC, Gupta RK, Qi K, Yee R, Leopoldo ZC, Morton DL. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am 1997;3:364-70.
13. Jones RC, Kelley M, Gupta RK, et al. Immune response to PMCV in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996;3:437-45.
14. Kelley MC, Jones RC, Gupta RK. et al. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early-stage melanoma. Cancer 1998;83: 1355-61.
15. Chester SJ, Maimonis P, Meitner PA, Vezeridis MP. An analysis of immuno-complexes for the detection of the early stages of colon cancer. Cancer 1990;65:1338-44.
16. Fleming ID, Cooper JS, Henson DE, et al, eds. AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven, 1998.